var path='https://www.tickertech.net'; function heading(heading) { document.write('
'+heading+' |
'+ ''+ ' |
'); } function hiLite(imgDocID,imgObjName) { document.images[imgDocID].src = eval(imgObjName + ".src"); } function showStatus(toshow) { window.status = toshow; } function checkChoose() { if (document.choose.ticker.value == "") { alert("Please enter symbols before clicking the go button"); return false; } else return true; } function popJT(url,name){ var xwid = screen.width; xwid = xwid - 10; javaticker = window.open(url,name,'width='+xwid+',height=100,resizable=yes,scrollbars=no,toolbar=no,location=no,directories=no,status=yes,menubar=no'); javaticker.opener.name="opener"; //javaticker.moveTo(0,30); } var allow = 0; var ref = ""+location; if ((ref.indexOf("cryptocurrencieschannel.com") > 0) || (ref.indexOf("cefchannel.com") > 0) || (ref.indexOf("bdcinvestor.com") > 0) || (ref.indexOf("tickertech.com") > 0) || (ref.indexOf("xxxx:") > 0) || (ref.indexOf("javascript:") > 0) || (ref.indexOf("filseclab.com") > 0) || (ref.indexOf("msnscache.com") > 0) || (ref.indexOf("toolbar.google.com") > 0) || (ref.indexOf("etfchannel.com") > 0) || (ref.indexOf("marketnewsvideo.com") > 0) || (ref.indexOf("news.google.com") > 0) || (ref.indexOf("dividendchannel.com") > 0) || (ref.indexOf("www.google.com") > 0) || (ref.indexOf("energystockchannel.com") > 0) || (ref.indexOf("metalschannel.com") > 0) || (ref.indexOf("portfoliochannel.com") > 0) || (ref.indexOf("canadastockchannel.com") > 0) || (ref.indexOf("theonlineinvestor.com") > 0) || (ref.indexOf("investhelp.com") > 0) || (ref.indexOf("preferredstockchannel.com") > 0) || (ref.indexOf("stockoptionschannel.com") > 0) || (ref.indexOf("holdingschannel.com") > 0) || (ref.indexOf("tickertech.net") > 0) || (ref.indexOf("historicalstockprice.com") > 0) || (ref.indexOf("splithistory.com") > 0) || (ref.indexOf("stocksplithistory.com") > 0) || (ref.indexOf("google.c") > 0) || (ref.indexOf("208.71.46.190") > 0) || (ref.indexOf("search.yahoo") > 0) || (ref.indexOf("sharesoutstandinghistory.com") > 0) || (ref.indexOf("marketcaphistory.com") > 0) || (ref.indexOf("ytdreturn.com") > 0) || (ref.indexOf("averageannualreturn.com") > 0) || (ref.indexOf("redinews.com") > 0) || (ref.indexOf("technicalanalysischannel.com") > 0) || (ref.indexOf("stockdma.com") > 0) || (ref.indexOf("stockrsi.com") > 0) || (ref.indexOf("stockmacd.com") > 0) || (ref.indexOf("topdividends.com") > 0) || (ref.indexOf("monthlydividendpayingstocks.com") > 0) || (ref.indexOf("nextearningsdate.com") > 0) || (ref.indexOf("pastearnings.com") > 0) || (ref.indexOf("historicalperatio.com") > 0) || (ref.indexOf("historicalearnings.com") > 0) || (ref.indexOf("webcache.googleusercontent.com") > 0)) { allow = 1; } function ShowTTIPage() { if (allow) { document.write('\n'); } if (allow) { document.write('
\n'); } if (allow) { document.write('4/15 - 8:30 AM \; \; | \n'); } if (allow) { document.write('Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO) in Women with ER+/HER2- Breast Cancer | \n'); } if (allow) { document.write('
4/12 - 1:32 PM \; \; | \n'); } if (allow) { document.write('Friday 4/12 Insider Buying Report: ATOS, TRDA [VIDEO] | \n'); } if (allow) { document.write('
4/11 - 8:30 AM \; \; | \n'); } if (allow) { document.write('Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference | \n'); } if (allow) { document.write('
4/9 - 11:59 AM \; \; | \n'); } if (allow) { document.write('Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen | \n'); } if (allow) { document.write('
4/1 - 4:00 PM \; \; | \n'); } if (allow) { document.write('Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update | \n'); } if (allow) { document.write('
3/19 - 8:30 AM \; \; | \n'); } if (allow) { document.write('Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient | \n'); } if (allow) { document.write('
3/18 - 8:30 AM \; \; | \n'); } if (allow) { document.write('Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements | \n'); } if (allow) { document.write('
3/12 - 8:30 AM \; \; | \n'); } if (allow) { document.write('Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors | \n'); } if (allow) { document.write('
3/6 - 8:30 AM \; \; | \n'); } if (allow) { document.write('Data from Atossa\'s Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting | \n'); } if (allow) { document.write('
2/22 - 8:30 AM \; \; | \n'); } if (allow) { document.write('Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study | \n'); } if (allow) { document.write('
2/7 - 8:30 AM \; \; | \n'); } if (allow) { document.write('Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial | \n'); } if (allow) { document.write('
1/9 - 8:30 AM \; \; | \n'); } if (allow) { document.write('Atossa Therapeutics Issues Letter to Shareholders | \n'); } if (allow) { document.write('
\n'); } if (allow) { document.write(' |